Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $95
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $86 to $95.
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $86 to $95.